In the latest close session, Merck (MRK) was down 2.15% at $126.78. This change lagged the S&P 500's 0.72% gain on the day.
Merck (NYSE:MRK) reported positive Phase 3 results for tulisokibart, an anti-TL1A monoclonal antibody in moderate-to-severe ...
Merck & Co., Inc. (NYSE:MRK) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 25, Merck & Co., Inc.
Merck remains in focus after important pipeline developments, new product approvals, and clinical progress strengthen discussions around future business growth and valuation.
Merck extends its bullish breakout from a pennant pattern, supported by strong volume and higher swing lows, with technical ...
Merck draws attention as healthcare strength, pharma activity, and defensive market rotation place large drugmakers back in ...
While the broader S&P Healthcare index has risen by 6% this year, and investors have generally favored healthcare stocks as a defensive strategy amid concerns over the economic impact of Trump’s ...
Asianet Newsable on MSN
MRK, NEUP stocks drop as Merck scraps another Alzheimer’s drug trial under Neuphoria partnership
Merck cited business reasons for the discontinuation of the investigational drug.
Merck & Co. Inc. (NYSE:MRK) on Tuesday shared topline results from the Phase 3 CORALreef Lipids trial evaluating the safety and efficacy of enlicitide decanoate for hypercholesterolemia on a moderate ...
Mixed stock index futures as tech rebounds: watch Micron earnings, Merck’s Keytruda approval, Wendy’s WSB surge, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results